12 Best 52-Week High Stocks to Buy Right Now

7. Disc Medicine, Inc. (NASDAQ:IRON)

52 Week Range: $30.82 – $97.11

Current Share Price as of December 4: $94.23

Year to date Gain: 50.12%

Stock Upside Potential: 24.39%

Number of Hedge Fund Holders: 34

Disc Medicine, Inc. (NASDAQ:IRON) is one of the best 52-week high stocks to buy right now. On November 20, analysts at Jefferies reiterated a Buy rating on the stock with a $127 price target. The research firm has echoed the company’s strong performance and continued momentum in 2026. It expects the momentum to be driven by the bitopertin approval as a treatment option for erythropoietic protoporphyria (EPP) and its potential launch early next year.

The company is staring at a tremendous opportunity following the Confirmed Pediatric Investigation Plan Verification (CNPV), which underscores unmet need around erythropoietic protoporphyria (EPP). Upcoming Phase 2 interim data for DISC-0974 in anemia myelofibrosis (MF) is also a potential catalyst.

Meanwhile, TD Cowen analyst Tara Bancroft reiterated a Buy rating on the stock on November 14, impressed by the promising outlook for bitopertin, a first-in-class treatment for erythropoietic protoporphyria (EPP). The drug is poised to capture significant market potential valued at $700 million.

Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes new treatments for serious hematologic diseases, such as those affecting red blood cells and iron metabolism. They focus on building a pipeline of therapies that target fundamental biological pathways, including heme biosynthesis and iron homeostasis, to help patients with conditions like erythropoietic protoporphyria (EPP).